News
GPCR
38.66
-2.25%
-0.89
Weekly Buzz: JNJ Wins FDA Nod; AXGN, HCWB Strike Deals; ROIV, AZN, GPCR Lead Clinical Trials
NASDAQ · 2d ago
Structure Therapeutics: The Amylin Data Changes The Math
Seeking Alpha · 4d ago
Structure Therapeutics Price Target Maintained With a $110.00/Share by Citizens
Dow Jones · 5d ago
Citizens Reiterates Market Outperform on Structure Therapeutics, Maintains $110 Price Target
Benzinga · 5d ago
Canaccord Genuity Remains a Buy on Structure Therapeutics, Inc. Sponsored ADR (GPCR)
TipRanks · 5d ago
Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR), Belite Bio, Inc. ADR (BLTE) and BridgeBio Oncology Therapeutics (BBOT)
TipRanks · 5d ago
Structure Therapeutics: Buy Rating Reaffirmed on Promising Obesity Pipeline and Extended Data, Price Target Maintained at $104
TipRanks · 5d ago
Structure weakness ‘disconnected’ from underlying data, says Jefferies
TipRanks · 5d ago
Analysts Are Bullish on These Healthcare Stocks: enGene Holdings (ENGN), Structure Therapeutics, Inc. Sponsored ADR (GPCR)
TipRanks · 5d ago
Structure obesity portfolio updates ‘encouraging,’ says Clear Street
TipRanks · 5d ago
Structure Therapeutics Advances Weight-Loss Pills With New Clinical Data
Benzinga · 5d ago
Structure Therapeutics falls after trial data for lead obesity drugs
Seeking Alpha · 5d ago
Structure Therapeutics Reports Positive Data From Oral Amylin And GLP-1 Programs
NASDAQ · 6d ago
Structure Therapeutics reports ACCG-2671, aleniglipron trial results
TipRanks · 6d ago
Structure Therapeutics Reports Positive ACCG-2671 Early Trial Results
TipRanks · 6d ago
Weekly Report: what happened at GPCR last week (0831-0904)?
Weekly Report · 09/07 09:08
Weekly Report: what happened at GPCR last week (0824-0828)?
Weekly Report · 08/31 09:09
Septerna: GPCR Programs May Be Experimental, But I'm Holding For The Long Term
Seeking Alpha · 08/28 22:00
NVO vs. GPCR: Which Obesity Stock Is the Better Buy Right Now?
NASDAQ · 08/26 12:19
Weekly Report: what happened at GPCR last week (0817-0821)?
Weekly Report · 08/24 09:09
More
Webull provides a variety of real-time GPCR stock news. You can receive the latest news about Structure Therapeutics Inc ADR through multiple platforms. This information may help you make smarter investment decisions.
About GPCR
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. It is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. It is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.